354 related articles for article (PubMed ID: 16980214)
41. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?
Galarza C; Valencia D; Tobón GJ; Zurita L; Mantilla RD; Pineda-Tamayo R; Rojas-Villarraga A; Rueda JC; Anaya JM
Clin Rev Allergy Immunol; 2008 Feb; 34(1):124-8. PubMed ID: 18270866
[TBL] [Abstract][Full Text] [Related]
42. [Immunology and rheumatic diseases. History and current aspects].
Bonomo L
Recenti Prog Med; 1976 Dec; 61(6):741-8. PubMed ID: 1088188
[No Abstract] [Full Text] [Related]
43. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?
Molloy ES; Calabrese LH
Autoimmun Rev; 2008 Dec; 8(2):144-6. PubMed ID: 18700172
[TBL] [Abstract][Full Text] [Related]
44. Relationship of Sjögren's syndrome to other connective tissue and autoimmune disorders.
Theander E; Jacobsson LT
Rheum Dis Clin North Am; 2008 Nov; 34(4):935-47, viii-ix. PubMed ID: 18984413
[TBL] [Abstract][Full Text] [Related]
45. B-cell lymphoproliferation in chronic inflammatory rheumatic diseases.
Hansen A; Lipsky PE; Dörner T
Nat Clin Pract Rheumatol; 2007 Oct; 3(10):561-9. PubMed ID: 17906611
[TBL] [Abstract][Full Text] [Related]
46. [Inhibitory effect of sera from patients with rheumatic diseases on EA-rosette formation].
Nasonov EL; Aleksandrova EN; Sura VV; Ivanova MM; Zimin IuI
Ter Arkh; 1983; 55(7):32-7. PubMed ID: 6604958
[No Abstract] [Full Text] [Related]
47. B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus.
Podolskaya A; Stadermann M; Pilkington C; Marks SD; Tullus K
Arch Dis Child; 2008 May; 93(5):401-6. PubMed ID: 18039744
[TBL] [Abstract][Full Text] [Related]
48. [B-cell depletion and primary Sjögren's syndrome: is there a role for rituximab?].
Atzeni F; Sarzi-Puttini P
Reumatismo; 2010; 62(2):87-8. PubMed ID: 20657883
[No Abstract] [Full Text] [Related]
49. SLE - Rituximab in lupus.
Eisenberg R
Arthritis Res Ther; 2003; 5(4):157-9. PubMed ID: 12823844
[TBL] [Abstract][Full Text] [Related]
50. Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab.
Ahmadi-Simab K; Lamprecht P; Nölle B; Ai M; Gross WL
Ann Rheum Dis; 2005 Jul; 64(7):1087-8. PubMed ID: 15958765
[No Abstract] [Full Text] [Related]
51. Long term treatment of rheumatoid arthritis with rituximab.
Caporali R; Caprioli M; Bobbio-Pallavicini F; Bugatti S; Montecucco C
Autoimmun Rev; 2009 Jun; 8(7):591-4. PubMed ID: 19393205
[TBL] [Abstract][Full Text] [Related]
52. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.
Dass S; Bowman SJ; Vital EM; Ikeda K; Pease CT; Hamburger J; Richards A; Rauz S; Emery P
Ann Rheum Dis; 2008 Nov; 67(11):1541-4. PubMed ID: 18276741
[TBL] [Abstract][Full Text] [Related]
53. The B cell in systemic lupus erythaematosus: a rational target for more effective therapy.
Driver CB; Ishimori M; Weisman MH
Ann Rheum Dis; 2008 Oct; 67(10):1374-81. PubMed ID: 17720723
[TBL] [Abstract][Full Text] [Related]
54. [Effect of glucocorticosteroid and cytotoxic therapy on the natural cytotoxicity in rheumatic diseases].
Aleksandrova EN; Nasonov EL
Ter Arkh; 1985; 57(8):34-7. PubMed ID: 4071433
[No Abstract] [Full Text] [Related]
55. [Antibody-dependent and natural cellular cytotoxic reactions in rheumatic diseases].
Aleksandrova EN; Zimin IuI; Nasonov EL
Ter Arkh; 1984; 56(10):130-6. PubMed ID: 6084315
[No Abstract] [Full Text] [Related]
56. Therapeutic targeting of B cells for rheumatic autoimmune diseases.
Engel P; Gómez-Puerta JA; Ramos-Casals M; Lozano F; Bosch X
Pharmacol Rev; 2011 Mar; 63(1):127-56. PubMed ID: 21245206
[TBL] [Abstract][Full Text] [Related]
57. Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases.
Md Yusof MY; Vital EM; McElvenny DM; Hensor EMA; Das S; Dass S; Rawstron AC; Buch MH; Emery P; Savic S
Arthritis Rheumatol; 2019 Nov; 71(11):1812-1823. PubMed ID: 31131994
[TBL] [Abstract][Full Text] [Related]
58. Use of rituximab in patients with systemic lupus erythematosus: an update.
García-Carrasco M; Jiménez-Hernández M; Escárcega RO; Mendoza-Pinto C; Galarza-Maldonado C; Sandoval-Cruz M; Zamudio-Huerta L; López-Colombo A; Cervera R
Autoimmun Rev; 2009 Feb; 8(4):343-8. PubMed ID: 19036350
[TBL] [Abstract][Full Text] [Related]
59. Updates on B-cell immunotherapies for systemic lupus erythematosus and Sjogren's syndrome.
Coca A; Sanz I
Curr Opin Rheumatol; 2012 Sep; 24(5):451-6. PubMed ID: 22871954
[TBL] [Abstract][Full Text] [Related]
60. [Difficulties in differential diagnosis of Sjögren's syndrome and systemic lupus erythematosus].
Krawiec P; Batko B; Skura A; Adamek-Guzik T; Cześnikiewicz-Guzik M; Krzanowski M; Rydz-Stryszowska I; Ryszawa N; Guzik TJ
Przegl Lek; 2006; 63(5):278-83. PubMed ID: 17036505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
